Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature

References

• Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518–527.
   PubMed Web of Science ®Google Scholar
• Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24:S3–S10.
   Google Scholar
• Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3–8.
   PubMedGoogle Scholar
• Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218–226.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 2003;127:930–934.
   PubMed Web of Science ®Google Scholar
• Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992;84:394–398.
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating natural history of HPV and anogenital cancer. Vaccine 2006;24(Suppl 3):42–51.
   Web of Science ®Google Scholar
• Hildesheim A, Schiffman MH, Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235–240.
   PubMed Web of Science ®Google Scholar
• Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415–1423.
   PubMed Web of Science ®Google Scholar
• Syrjänen K, Syrjänen S. Papillomavirus infections in human pathology. Chichester (UK): John Wiley & Sons2000. pp 1–615.
   Google Scholar
• Cho NH, Kim YT, Kim JW. Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. Yonsei Med J 2002;43:722–728.
   Google Scholar
• Clarke B, Chetty R. Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2001;82:238–246.
   PubMed Web of Science ®Google Scholar
• Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999;35:531–539.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Tana R, Genazzani AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 2009;69: 12–27.
   PubMedGoogle Scholar
• Adams PD. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta 2001;1471:M123–M133.
   PubMed Web of Science ®Google Scholar
• Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 2004;117:2173–2181.
   PubMed Web of Science ®Google Scholar
• Schulze A, Mannhardt B, Zerfass-Thome K, Zwerschke W, Jansen-Dürr P. Anchorage independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16. J Virol 1998;72:2323–2334.
   PubMedGoogle Scholar
• Southern SA, Herrington CS. Differential cell cycle regulation by low- and high-risk human papillomaviruses in low-grade squamous intraepithelial lesions of the cervix. Cancer Res 1998;58:2941–2945.
   Google Scholar
• Hengst L, Reed SI. Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998;227:25–41.
   PubMedGoogle Scholar
• Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731–737.
   PubMed Web of Science ®Google Scholar
• Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001;92:57–70.
   PubMed Web of Science ®Google Scholar
• Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997;11:2090–2100.
   PubMed Web of Science ®Google Scholar
• Santopietro R, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, Podistov J, Chemeris G, Sozaeva L, Lipova E, et al. Cell cycle regulators p105, p107, Rb2/p130, E2F4, p21CIP1/WAF1, cyclin A in predicting CIN, high-risk human papillomavirus infections and their outcome in women screened in three new independent states of the former Soviet Union. Cancer Epidemiol Biomarkers Prev 2006;15:1250–1256.
   Google Scholar
• Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, Peto J. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000;83:1565–1572.
   PubMed Web of Science ®Google Scholar
• Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085–1092.
   PubMed Web of Science ®Google Scholar
• Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007;23:213–227.
   PubMed Web of Science ®Google Scholar
• Klumb EM, Araújo ML Jr, Jesus GR, Santos DB, Oliveira AV, Albuquerque EM, Macedo JM. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol 2010;16:153–157.
   PubMed Web of Science ®Google Scholar
• Einstein MH, Phaëton R. Issues in cervical cancer incidence and treatment in HIV. Curr Opin Oncol 2010;22:449–455.
   PubMed Web of Science ®Google Scholar
• Finan RR, Musharrafieh U, Almawi WY. Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. Clin Microbiol Infect 2006;12: 927–930.
   Google Scholar
• Kwaśniewska A, Korobowicz E, Zdunek M, Skoczyński M, Kwaśniewski W, Daniłoś J, Goździcka-Józefiak A. Prevalence of Chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with human papillomavirus detected in paraffin-sectioned samples. Eur J Gynaecol Oncol 2009;30:65–70.
   Google Scholar
• Brinton LA, Schairer C, Haenszel W, Stolley P, Lehman HF, Levine R, Savitz DA. Cigarette smoking and invasive cervical cancer. JAMA 1986;255:3265–3269.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Engholm G, Dahl C, Bock JE. Case-control study of risk factors for cervical squamous cell neoplasia in Denmark. IV: role of smoking habits. Eur J Cancer Prev 1996;5:359–365.
   Google Scholar
• Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angström T, Dillner J. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82:1332–1338.
   PubMed Web of Science ®Google Scholar
• Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, de Sanjosé S, Muñoz N; IARC Multi-centre Cervical Cancer Study Group. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case – control study. Cancer Causes Control 2003;14:805–814.
   PubMed Web of Science ®Google Scholar
• Castellsague X, Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis – role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;31:20–28.
   PubMedGoogle Scholar
• Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, Hirai Y, Mitsuhashi A, Fujii T, Iwasaka T, et al. Tobacco smoking and regression of low-grade cervical abnormalities. Cancer Sci 2010;101:2065–2073.
   PubMed Web of Science ®Google Scholar
• Prokopczyk B, Cox JE, Hoffmann D, Waggoner SE. Identification of tobaccospecific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 1997;89:868–873.
   PubMedGoogle Scholar
• Melikian AA, Sun P, Prokopczyk B, El-Bayoumy K, Hoffmann D, Wang X, Waggoner S. Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Lett 1999;146:127–134.
   PubMed Web of Science ®Google Scholar
• Poppe WA, Ide PS, Drijkoningen MP, Lauweryns JM, Van Assche FA. Tobacco smoking impairs the local immunosurveillance in the uterine cervix. An immunohistochemical study. Gynecol Obstet Invest 1995;39:34–38.
   Web of Science ®Google Scholar
• Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 2009;9:377–384.
   PubMed Web of Science ®Google Scholar
• Alam S, Conway MJ, Chen HS, Meyers C. The cigarette smoke carcinogen benzo[a]pyrene enhances human papillomavirus synthesis. J Virol 2008;82:1053–1058.
   PubMed Web of Science ®Google Scholar
• Sundberg K, Johansson AS, Stenberg G, Widersten M, Seidel A, Mannervik B, Jernström B. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998;19:433–436.
   PubMed Web of Science ®Google Scholar
• Jee SH, Lee JE, Kim S, Kim JH, Um SJ, Lee SJ, Namkoong SE, Park JS. GSTP1 polymorphism, cigarette smoking and cervical cancer risk in Korean women. Yonsei Med J 2002;43:712–716.
   PubMed Web of Science ®Google Scholar
• Meeuwis KA, van Rossum MM, van de Kerkhof PC, Hoitsma AJ, Massuger LF, de Hullu JA. Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients. Transpl Int 2010;23:191–199.
   Google Scholar
• Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancy in systemic lupus erythematosus: what have we learned? Best Pract Res Clin Rheumatol 2009;23:539–547.
   PubMedGoogle Scholar
• Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009;136:451–458.
   PubMed Web of Science ®Google Scholar
• Lees CW, Critchley J, Chee N, Beez T, Gailer RE, Williams AR, Shand AG, Arnott ID, Satsangi J. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis 2009;15:1621–1629.
   PubMed Web of Science ®Google Scholar
• Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet Gynecol 2000;96:403–409.
   PubMed Web of Science ®Google Scholar
• Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, Wright TC. Incidence of cervical squamous intraepithelial lesions in HIV-Infected Women. JAMA 2000;283:1031–1037.
   PubMed Web of Science ®Google Scholar
• Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV) positive and HIV-negative women. J Infect Dis 2001;184:682–690.
   PubMed Web of Science ®Google Scholar
• Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano DD, Hall C, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003;95:1062–1071.
   PubMed Web of Science ®Google Scholar
• Mogtomo ML, Malieugoue LC, Djiepgang C, Wankam M, Moune A, Ngane AN. Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy. Infect Agent Cancer 2009;3:4–9.
   Google Scholar
• Hawes SE, Critchlow CW, Faye Niang MA, Diouf MB, Diop A, Toure P, Aziz Kasse A, Dembele B, Salif Sow P, Coll-Seck AM, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003;188:555–563.
   PubMed Web of Science ®Google Scholar
• Moukassa D, N'Golet A, Lingouala LG, Eouani ML, Samba JB, Mambou JV, Ompaligoli S, Moukengue LF, Taty-Pambou E. Precancerous lesions of the uterine cervix in Pointe-Noire, Congo. Med Trop 2007;67:57–60.
   Google Scholar
• Yamada R, Sasagawa T, Kirumbi LW, Kingoro A, Karanja DK, Kiptoo M, Nakitare GW, Ichimura H, Inoue M. Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. J Med Virol 2008;80:847–855.
   PubMed Web of Science ®Google Scholar
• de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449–5455.
   PubMed Web of Science ®Google Scholar
• Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, Mastrorilli E, Taccagni G, Lazzarin A, Uberti-Foppa C. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001;184:547–551.
   PubMed Web of Science ®Google Scholar
• Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, Moxley M, Palefsky J, Sacks H, Burk RD, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004;96:1070–1076.
   PubMedGoogle Scholar
• Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000;343:702–709.
   PubMed Web of Science ®Google Scholar
• Stephens HA. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol 2005;26:41–47.
   PubMed Web of Science ®Google Scholar
• Chan DP, Cheung TH, Tam AO, Cheung JL, Yim SF, Lo KW, Siu NS, Zhou DX, Chan PK. Risk association between human leukocyte antigen-A allele and high-risk human papillomavirus infection for cervical neoplasia in Chinese women. J Infect Dis 2005;192:1749–1756.
   Google Scholar
• Madeleine MM, Johnson LG, Smith AG, Hansen JA, Nisperos BB, Li S, Zhao LP, Daling JR, Schwartz SM, Galloway DA. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res 2008;68: 3532–3539.
   PubMed Web of Science ®Google Scholar
• Hosono S, Kawase T, Matsuo K, Watanabe M, Kajiyama H, Hirose K, Suzuki T, Kidokoro K, Ito H, Nakanishi T, et al. HLA-A alleles and the risk of cervical squamous cell carcinoma in Japanese women. J Epidemiol 2010;20:295–301.
   Google Scholar
• Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci 2003;997:199–208.
   PubMed Web of Science ®Google Scholar
• Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190(4 Suppl):S5–22.
   PubMed Web of Science ®Google Scholar
• Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385–389.
   PubMed Web of Science ®Google Scholar
• Shapiro S, Rosenberg L, Hoffman M, Kelly JP, Cooper DD, Carrara H, Denny LE, du Toit G, Allan BR, Stander IA, et al. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control 2003;14:485–495.
   PubMed Web of Science ®Google Scholar
• Green J, Berrington de Gonzalez A, Sweetland S, Beral V, Chilvers C, Crossley B, Deacon J, Hermon C, Jha P, Mant D, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. Br J Cancer 2003;89:2078–2086.
   PubMed Web of Science ®Google Scholar
• Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, Franceschi S, Beral V. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159–1167.
   PubMed Web of Science ®Google Scholar
• Berrington de Gonzalez A, Sweetland S, Green J. Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. Br J Cancer 2004;90:1787–1791.
   PubMed Web of Science ®Google Scholar
• Moodley J. Combined oral contraceptives and cervical cancer. Curr Opin Obstet Gynecol 2004;16:27–29.
   Google Scholar
• , International Collaboration of Epidemiological Studies of Cervical CancerAppleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370:1609–1621.
   PubMed Web of Science ®Google Scholar
• Li C, Wu M, Wang J, Zhang S, Zhu L, Pan J, Zhang W. A population-based study on the risks of cervical lesion and human papillomavirus Infection among women in Beijing, People's Republic of China. Cancer Epidemiol Biomarkers Prev 2010;19:2655–2564.
   Google Scholar
• Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989;70:2227–2232.
   PubMed Web of Science ®Google Scholar
• Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L. Hormonal contraception and risk of cancer. Hum Reprod Update 2010;16:631–650.
   PubMed Web of Science ®Google Scholar
• Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010;82:221–229.
   PubMed Web of Science ®Google Scholar
• Schmeink CE, Massuger LF, Lenselink CH, Quint WG, Melchers WJ, Bekkers RL. Effect of the menstrual cycle and hormonal contraceptives on human papillomavirus detection in young, unscreened women. Obstet Gynecol 2010;116:67–75.
   Google Scholar
• Gavric-Lovrec V, Takac I. Use of various contraceptives and human papillomavirus 16 and 18 infections in women with cervical intraepithelial neoplasia. Int J STD AIDS 2010;21:424–427.
   Google Scholar
• Marks M, Gravitt P, Gupta S, Liaw K, Kim E, Tadesse A, Phongnarisorn C, Wootipoom V, Yuenyao P, Vipupinyo C, et al. The association of hormonal contraceptive use and HPV prevalence. Int J Cancer, in press.
   Google Scholar
• de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2003;103:705–708.
   PubMed Web of Science ®Google Scholar
• Moodley M, Moodley J, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003;13:103–110.
   PubMed Web of Science ®Google Scholar
• Hellberg D, Stendahl U. The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. Anticancer Res 2005;25:3041–3046.
   PubMedGoogle Scholar
• Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E, Woodworth CD. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer Res 2000;60:4289–4298.
   Google Scholar
• Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. Neurosci Biobehav Rev 2000;24:627–638.
   PubMed Web of Science ®Google Scholar
• Loy RA, Loukides JA, Polan ML. Ovarian steroids modulate human monocyte tumor necrosis factor alpha messenger ribonucleic acid levels in cultured human peripheral monocytes. Fertil Steril 1992;58:733–739.
   Web of Science ®Google Scholar
• Konecna L, Yan MS, Miller LE, Scholmerich J, Falk W, Straub RH. Modulation of IL-6 production during the menstrual cycle in vivo and in vitro. Brain Behav Immun 2000;14:49–61.
   PubMedGoogle Scholar
• Polan ML, Loukides J, Nelson P, Carding S, Diamond M, Walsh A, Bottomly K. Progesterone and estradiol modulate interleukin-1 beta messenger ribonucleic acid levels in cultured human peripheral monocytes. J Clin Endocrinol Metab 1989;69:1200–1206.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Marshall GD Jr. Perimenstrual alterations in type-1/type-2 cytokine balance of normal women. Ann Allergy Asthma Immunol 1999;83:222–228.
   PubMed Web of Science ®Google Scholar
• Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999;103:282–288.
   PubMed Web of Science ®Google Scholar
• Rogers A, Eastell R. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone 2001;29:30–34.
   PubMed Web of Science ®Google Scholar
• Prieto G A, Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology 2006;118:58–65.
   Google Scholar
• Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol 2003;38:13–22.
   PubMed Web of Science ®Google Scholar
• Mjosberg J, Svensson J, Johansson E, Hellstrom L, Casas R, Jenmalm MC, Boij R, Matthiesen L, Jonsson JJ, Ernerudh J. Systemic reduction of functionally suppressive CD4dim CD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol. J Immunol 2009;183:759–769.
   PubMed Web of Science ®Google Scholar
• Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989;44:833–839.
   PubMed Web of Science ®Google Scholar
• Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy. Long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327–332.
   PubMed Web of Science ®Google Scholar
• Parazzini F, La Vecchia C, Negri E, Franceschi S, Moroni S, Chatenoud L, Bolis G. Case-control study of oestrogen replacement therapy and risk of cervical cancer. BMJ 1997; 315:85–88.
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009;1:1–11.
   Google Scholar
• Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987;26:169–177.
   PubMed Web of Science ®Google Scholar
• Biglia N, Gadducci A, Ponzone R, Roagna R, Sismondi P. Hormone replacement therapy in cancer survivors. Maturitas 2004;48:333–346.
   PubMed Web of Science ®Google Scholar
• Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int 2010;16:89–93.
   PubMedGoogle Scholar
• Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010;65:190–197.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757–1765.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271–278.
   PubMed Web of Science ®Google Scholar
• Adams M, Jasani B, Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007;25:3007–3013.
   PubMed Web of Science ®Google Scholar
• Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 2010;16:217–230.
   PubMed Web of Science ®Google Scholar
• Marks M, Gravitt P, Burk R, Studentsov Y, Farzadegan H, Klein S. Progesterone and 17beta-estradiol enhance regulatory responses to HPV 16 VLP in peripheral blood mononuclear cells from healthy women. Clin Vaccine Immunol 2010;17:609–617.
   Google Scholar
• Buckner JH, Ziegler SF. Functional analysis of FOXP3. Ann N Y Acad Sci 2008;1143:151–169.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24:78–89.
   Web of Science ®Google Scholar
• Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357: 1579–1588.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095–1101.
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249–257.
   PubMed Web of Science ®Google Scholar
• von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229–2242.
   PubMed Web of Science ®Google Scholar
• Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008;9:937–945.
   PubMed Web of Science ®Google Scholar
• Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol Oncol 2010;120:89–93.
   Google Scholar
• Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang SC, Pater MM, Pater A. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997;75:1410–1416.
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88–99.
   PubMedGoogle Scholar